Pressure-reducing eye drop patents in dispute
05-07-2022
Regeneron convinces PTAB to review Novartis syringe patent
28-10-2021
Regeneron asks court to dismiss COVID-19 tech patent suit
24-08-2021
The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Regeneron Pharmaceuticals, Eylea, PTAB, Mylan Pharmaceuticals, Novartis
